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ABSTRACT: Heparan sulfate (HS) polysaccharides are
ubiquitous in animal tissues as components of proteoglycans,
and they participate in many important biological processes.
HS carbohydrate chains are complex and can contain rare
structural components such as N-unsubstituted glucosamine
(GlcN). Commercially available HS preparations have been
invaluable in many types of research activities. In the course of
preparing microarrays to include probes derived from HS
oligosaccharides, we found an unusually high content of GlcN
residue in a recently purchased batch of porcine intestinal
mucosal HS. Composition and sequence analysis by mass
spectrometry of the oligosaccharides obtained after heparin
lyase III digestion of the polysaccharide indicated two and
three GlcN in the tetrasaccharide and hexasaccharide fractions, respectively. 1H NMR of the intact polysaccharide showed that
this unusual batch diﬀered strikingly from other HS preparations obtained from bovine kidney and porcine intestine. The very
high content of GlcN (30%) and low content of GlcNAc (4.2%) determined by disaccharide composition analysis indicated that
N-deacetylation and/or N-desulfation may have taken place. HS is widely used by the scientiﬁc community to investigate HS
structures and activities. Great care has to be taken in drawing conclusions from investigations of structural features of HS and
speciﬁcities of HS interaction with proteins when commercial HS is used without further analysis. Pending the availability of a
validated commercial HS reference preparation, our data may be useful to members of the scientiﬁc community who have used
the present preparation in their studies.
Heparan sulfate (HS) is ubiquitous in animal tissuesoccurring as components of proteoglycans. They
participate in many important biological processes interacting
with a wide range of proteins, such as cytokines and
chemokines,1 ﬁbroblast growth factors,2 and the coagulation
regulator antithrombin, in addition to pathogenic agents
involved in inﬂammation3 and amyloid diseases.4 HS
polysaccharides are complex carbohydrate chains. Alternating
(1-4)-linked α-N-acetylglucosamine (GlcNAc) and β-glucur-
onic acid (GlcA) comprise most of their primary sequence with
heterogeneity arising from diﬀerent degrees of N-deacetylation/
N-sulfation, isomerization of GlcA to iduronic acid (IdoA), and
variation in O-sulfation. The most highly sulfated regions of HS
contain 3 sulfates per disaccharide unit, 6-O- and 2-N-
disulfoglucosamine and 2-O-sulfo-IdoA (GlcNS6S-IdoA2S)
whereas the least sulfated regions contain the GlcNAc-GlcA
disaccharide unit. There also occur some less common
structural elements, such as 3-O-sulfo or N-unsubstituted
glucosamine (GlcN).
In the past, the presence of GlcN in HS chains was generally
of little concern. The importance of this rare structural
component was recognized only in the 1990s5−11 and has
attracted various interest.12−15 Although this unusual residue in
HS can be formed as an artifactual product introduced during
preparation and puriﬁcation (particularly at low pH), its
occurrence in the HS chain is now thought to be formed
through regulated, incomplete action of an N-deacetylase/N-
sulfotransferase.16 GlcN amounts to 0.7 to 4% of total
glucosamine in HS16 or 1 to 2 residues in each HS chain17
depending on the source. The GlcN residue occurs largely near
the polysaccharide-protein linkage region of HS chains, with
less frequent peripheral location.16 The GlcN unit has been
shown to be part of HS antigens recognized by monoclonal
antibodies 10E411,18 and JM403.5,19 The antigen recognized by
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10E4 antibody is closely associated with prion lesions in the
brain of mice infected with scrapie.20
Commercially available HS polysaccharides have been
invaluable in many types of research activities. HS isolated
from bovine kidney is available from Sigma but is expensive.
Porcine intestinal mucosa is a major source for the manufacture
of heparin sodium salt used in medicine, and HS can be
extracted from the mixture of glycosaminoglycans (GAGs)
remaining after the extraction of heparin.21−23 HS from this
source is available from Celsus. We have in the past used Celsus
HS to investigate the presence of free GlcN residue and its
recognition by monoclonal antibody 10E412 and lyase III
activity toward GlcN residues.12
In the present study, during the preparation of GAG
microarrays24 to include probes from oligosaccharide fractions
of HS, we found an unusually high content of free GlcN residue
in the batch HO-01214, recently ordered from Celsus.
Although we have in the past identiﬁed GlcN in HS from
Celsus, its incidence in batch HO-01214 was exceptionally high.
For preparation of oligosaccharides, HO-01214 of HS was
partially depolymerized by heparin lyase III. The digestion
product was fractionated by gel ﬁltration chromatography on
Bio-Gel P6 (Supplemental Figure S1) and the oligosaccharide
fragments were analyzed by electrospray mass spectrometry
(ESI-MS).25
The MS results together with the derived composition are
listed in Table 1 and representative spectra in Figure 1a−d.
Oligosaccharide fraction F1 contains exclusively the disacchar-
ide ΔUA-GlcNS, but to our surprise, a very high content of free
GlcN-containing components were found in the tetra- (F2) and
larger oligosaccharide fractions, e.g., hexa-, octa-, and
decasaccharides (F3, F4, and F5, respectively). In fraction
F2a, the main component at m/z 673 (Figure 1b) is a
tetrasaccharide which contains two GlcN residues. We could
also readily identify up to three GlcN in a hexasaccharide and
four GlcN in an octasaccharide sequence (Table 1).
Collision-induced dissociation and tandem MS (ESI-CID-
MS/MS) for sequence analysis was carried out to verify the
presence of the unusual consecutive GlcN residues in the linear
chain.12 As shown in the spectra, indeed tetrasaccharide (Figure
1e) and hexasaccharide (Supplemental Figure S2a) with
exclusive GlcN can be conﬁrmed.
Among the identiﬁed main ions in the di- to deca-saccharide
fractions, only one component, m/z 715, present in fraction F3,
contains a single N-acetylglucosamine residue with the
sequence of ΔUA-GlcN-UA-GlcNAc (Table 1 and Supple-
mental Figure S2b). All the other ion species identiﬁed contain
GlcN and/or GlcNS without GlcNAc. Although sequences with
glucosamine fully N-sulfated (GlcNS) can be found in the di-
and tetrasaccharide fractions (e.g., ΔUA-GlcNS-UA-GlcNS),
only partially N-sulfated glucosamine were present in the higher
oligomeric fractions (e.g., ΔUA-GlcN-UA-GlcN-UA-GlcNS).
This is in complete contrast to the data we obtained in our
early study11 using a previous batch of HS from the same
source (see below), in which only a single GlcN was identiﬁed
that was located within an unusual nonsulfated tetrasaccharide
sequence. To ensure that in the present study the large amount
of GlcN was not produced during our enzymatic depolymeriza-
tion and fractionation procedure, we carried out 1H NMR
analysis of the intact HO-01214 polysaccharide in comparison
with other HS preparations obtained from bovine kidney and
porcine intestine.
1H NMR spectra of HS from bovine kidney (Sigma), HS
batch HO-01214 from Celsus, and samples of porcine mucosal
HS 1 from our own laboratory, HS-1B and HS-1A21 are shown
in parts a, b, c, and d of Figure 2, respectively. Resonances at
4.37 ppm, consistent with H1 of either GlcNAc or GlcNS,26 are
seen in the four HS spectra (Figure 2), but signals from IdoA2S
are weak in HO-01214. Signals at 3.38 ppm, attributable to H2
of GlcA, are strong in the HS samples, though less marked in
HO-01214 (Figure 2b). It is not easy to distinguish between N-
sulfo and N-unsubstituted glucosamine in the 1H spectrum;27 a
prominent peak at 5.59 ppm in the spectrum of HO-01214 is
Table 1. ESI-MS of Oligosaccharide Fractions of Celsus HO-01214 Obtained by Heparin Lyase III Digestion and Bio-Gel P6
Fractionation
aRelative intensity (% relative to the base peak) is shown in parentheses; when the ion is the base peak, relative intensity (100%) was not shown.
bAlthough both ΔUA-GlcNS-UA-GlcN and ΔUA-GlcN-UA-GlcNS are possible, lyase III does not favor GlcN-UA for cleavage,12 and therefore
ΔUA-GlcNS-UA-GlcN is not proposed as the main tetrasaccharide product.
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consistent with nonacetylated GlcN or GlcNS linked to GlcA.27
The most obvious diﬀerence between HO-01214 and the other
two HS spectra lies in the methyl signal of the acetyl group at
about 2.04 ppm. The intensity of this peak, compared with that
of the anomeric and ring proton signals, is high for the HS
spectra in Figure 2a,c,d but weak in the HO-01214 spectrum
(Figure 2b). This indicates that the degree of N-acetylation on
the amino sugar is much lower for HO-01214 than is the case
for the other two porcine HS samples. 1H NMR spectra for
three preparations of porcine mucosal HS-1C, prepared as
described by Casu et al.,21 and HO-10697 and HO-10095, very
old batches from Celsus, are also shown in Supplemental Figure
S3; all of them contain the same prominent acetyl methyl signal
at 2.04 ppm.
The ratios of IdoA/GlcA for the abnormal HO-01214 and
two other porcine HS preparations (HS-1B and HO-10095)
were calculated based on the integrated anomeric cross-peaks in
their 13C−1H HSQC NMR spectra (Supplemental Figure S4).
The ratio of IdoA/GlcA for HO-01214 at 0.7 (Supplemental
Table S1) is similar to that of the two normal porcine HS
preparations, HS-1B and HO-10095 (0.6 and 0.9, respectively).
Disaccharide-composition analysis28 was next carried out to
quantitatively assess the content of the free GlcN in HO-01214
in comparison with three porcine intestinal HS samples, HS-
1A, HO-10095, and HO-10697, together with US Pharmaco-
peia heparin and chemically N-desulfated heparin (CNDS) as
Figure 1. Negative-ion ESI-MS and CID-MS/MS spectra of selected
HS-01214 oligosaccharide fractions. Mass spectra of the ﬁrst four
fractions (see Supplemental Figure S1) are shown: (a) Fraction 1; (b)
Fraction 2a; (c) Fraction 2b; and (d) Fraction 3. Product-ion spectrum
of Fraction F2a using [M − H]− at m/z 673 as the precursor is shown
in part e; the observed fragmentation was consistent to the proposed
structure.
Figure 2. 1H NMR spectra of diﬀerent HS preparations: (a) bovine
kidney HS obtained from Sigma; (b) porcine intestinal HS, HO-
01214, obtained from Celsus Laboratories; (c) porcine intestinal HS-
1B; and (d) porcine intestinal HS-1A. ×, Signal from an unidentiﬁed
impurity in this sample.
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controls. The percentages of the 12 potential disaccharide
constituents were obtained (Table 2) and these include four
GlcNAc-containing, 4 GlcNS-containing, and 4 possible GlcN-
containing disaccharides. A total of 30% of GlcN was found in
HO-01214, mainly in the form of ΔUA-GlcN (26%) together
with some minor (3.8%) ΔUA(2S)-GlcN(6S). This is very high
compared with the other three porcine intestinal HS, HS-1A,
HO-10095, and HO-10697, (1.6−5.8%) while the content of
ΔUA-GlcNAc is extremely low (1.7%, Table 2) that is identical
to the CNDS.
It became clear that the HO-01214 of HS received from
Celsus is very diﬀerent from all other HS preparations analyzed.
The content of GlcNAc is much below 75% as deﬁned by
Celsus in the product information. The very high content of
GlcN and low content of GlcNAc may indicate a N-
deacetylation and/or N-desulfation procedure has taken place.
The unusual structure feature of HS HO-01214 identiﬁed
here could not simply be a batch-to-batch variation issue.
According to the manufacturer’s product information, HS is a
“fraction of crude heparin of porcine mucosal tissue” and
“comprising primarily ΔUA-GlcNAc (∼75%)”. On the basis of
the data obtained from MS sequence analysis of the
oligosaccharide fragments, NMR of the polysaccharide, and
disaccharide composition analysis described above, HO-01214
does not meet this criterion. NMR spectroscopy also shows
that it is considerably diﬀerent from other sources of porcine
intestinal HS.21,22,27,29
HS prepared by Celsus has been valuable to the scientiﬁc
community in analytical applications to develop methods for
chromatography30,31 and sequencing of the complex mole-
cule,32−35 as a standard for quantitation36 and stability
studies,37 in biomedical application to investigate its activity
to interact with oligopeptides38,39 and a number of
proteins40−42 including growth factors,43,44 endostatin,45,46
and HIV gp120,47 and as controls in the investigation of HS
structural transition in embryonic stem cells.48
Complex polysaccharides isolated from natural sources
oﬀered for use in research laboratories are not regulated as
closely as similar preparations used in medicine, such as the
HS-related compound heparin.49 Manufacturers need to
implement careful control of this complex natural product
and care has to be taken by users in drawing conclusions
particularly from investigations of structural features of HS and
speciﬁcities of HS-protein interactions when HS is from a
commercial source. Pending the availability of a validated
commercial HS reference preparation, it is hoped that our data
will be useful for members of the scientiﬁc community who




The Supporting Information is available free of charge on the
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